You are here

  • Home
  • Archive
  • Volume 20, Issue 2
  • Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemother…

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy

Authors

  1. Address correspondence and reprint requests to Aristotelis Bamias, MD, PhD, Oncology Unit, Alexandra Hospital, 80 Vas. Sofias Ave, 115 28 Athens, Greece. E-mail: abamias{at}med.uoa.gr.

Citation

Bozas G, Terpos E, Gika D, et al
Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy
International Journal of Gynecologic Cancer 2010;20:248-254.

Publication history

  • Received October 5, 2009
  • First published February 1, 2010.
Online issue publication 
February 26, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2010 by IGCS and ESGO